Verisk Analytics
VRSK
$171.59
+0.28%
Verisk Analytics is a leading data, analytics, and technology provider operating within the property-casualty insurance industry, offering critical solutions for underwriting, claims, and catastrophe modeling. The company holds a dominant market position as an essential, data-driven partner to insurers, having evolved from a non-profit industry association into a for-profit public entity. The current investor narrative is heavily focused on the stock's severe price dislocation, as it trades near multi-year lows following a significant decline, raising debates about whether this represents a deep value opportunity in a stable business or reflects fundamental challenges within its core insurance client base.…
VRSK
Verisk Analytics
$171.59
Investment Opinion: Should I buy VRSK Today?
Rating: Hold. The core thesis is that VRSK presents a high-risk, high-potential-reward deep value situation where severe price dislocation conflicts with fundamental leverage and growth concerns, making it unsuitable for anything but a speculative allocation until the trend reverses.
Supporting evidence includes a forward P/E of 19.76x based on expected EPS recovery, but this is juxtaposed against a high trailing P/E of 34.24x and modest 5.87% revenue growth. Profitability is strong with a 25.32% net margin, and cash flow is robust at $1.19B TTM. However, the extreme debt-to-equity of 16.3 overshadows these strengths. The stock trades just 9.1% above its 52-week low, indicating massive technical damage, yet recent institutional analyst upgrades suggest a value narrative is emerging.
The thesis would upgrade to a Buy if the stock establishes a technical base above $180 and QoQ revenue growth re-accelerates above 7%, confirming the earnings recovery story. It would downgrade to a Sell if the price breaks decisively below the $155.94 support level or if quarterly free cash flow shows material deterioration, calling debt serviceability into question. Relative to its own battered history, the stock is fairly valued for the risks it carries, but it is not yet demonstrably cheap enough to outweigh the clear bearish momentum and balance sheet concerns.
Sign up to view all
VRSK 12-Month Price Forecast
VRSK is a classic 'fallen angel' presenting a complex risk/reward. The stable, cash-generative business model is attractive at these prices, but it is shackled by an alarming debt load and a completely broken chart. The neutral stance reflects the high probability (50%) base case of sideways consolidation, as bulls and wrestle with these opposing forces. The stance would upgrade to bullish on a confirmed technical reversal above $200 accompanied by evidence of deleveraging. It would turn bearish on a breakdown below $155, which would signal the fundamental risks are overwhelming the value proposition.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Verisk Analytics's 12-month outlook, with a consensus price target around $223.07 and implied upside of +30.0% versus the current price.
Average Target
$223.07
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$137 - $223
Analyst target range
Analyst coverage for VRSK appears limited, with only 5 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the analyst data set. The institutional ratings show recent activity from major firms, with actions in March 2026 including a reiteration of 'Outperform' by RBC Capital and an upgrade to 'Strong Buy' by Raymond James, alongside maintained 'Overweight' ratings from Wells Fargo and JP Morgan. The absence of a quantifiable average target price and implied upside/downside calculation indicates insufficient consensus data is available for a precise sentiment reading. The pattern from institutional ratings suggests a leaning towards bullish or neutral stances among covering firms, but the limited number of analysts and lack of price targets implies this is not a widely followed large-cap stock, which can contribute to higher volatility and less efficient price discovery, as seen in its steep decline.
Bulls vs Bears: VRSK Investment Factors
The investment debate for VRSK centers on a clash between deep value and fundamental risk. The bull case is anchored in the stock's severe price dislocation, strong underlying profitability, and analyst expectations for an earnings recovery. The bear case is dominated by extreme financial leverage, a broken technical chart, and a valuation that still appears rich relative to its modest growth. Currently, the bearish evidence appears stronger due to the persistence of the downtrend and the tangible, quantifiable risk posed by the debt-to-equity ratio of 16.3. The single most important tension is whether the company's robust free cash flow ($1.19B TTM) can sustainably manage its high debt burden while growth remains in the low single digits, or if the leverage will trigger further multiple compression and price discovery to the downside.
Bullish
- Strong Profitability & Cash Flow: VRSK maintains robust profitability with a Q4 2025 net margin of 25.32% and generated $1.19 billion in trailing twelve-month free cash flow. This strong cash generation provides a financial cushion and capacity to service its high debt load.
- Essential, Recurring Business Model: As a leading data and analytics provider to the property-casualty insurance industry, VRSK operates an essential, recurring revenue business. This is evidenced by stable, albeit modest, sequential quarterly revenue throughout 2025, averaging around $768 million per quarter.
- Analyst EPS Growth Expectations: Analysts forecast a significant earnings recovery, with the forward P/E of 19.76x being substantially lower than the trailing P/E of 34.24x. The average EPS estimate for the next period is $12.35, implying strong year-over-year growth from the Q4 2025 EPS of $1.42.
- Institutional Analyst Support: Recent institutional ratings from major firms like Raymond James (upgraded to Strong Buy) and RBC Capital (reiterated Outperform) suggest professional analysts see value at current depressed levels, providing a counter-narrative to the technical weakness.
Bearish
- Extreme Financial Leverage: The company's debt-to-equity ratio of 16.30 is exceptionally high, representing a major financial risk. This leverage amplifies risks in a rising interest rate environment and constrains financial flexibility.
- Severe Technical Downtrend: The stock is in a pronounced downtrend, down 45.57% over one year and 6.24% over three months, trading perilously close to its 52-week low. The negative relative strength of -73.45% versus the S&P 500 indicates persistent, severe underperformance.
- Modest, Non-Accelerating Growth: Revenue growth is modest at 5.87% YoY in Q4 2025, and sequential quarterly revenue in 2025 was flat ($753M to $779M). For a stock with a trailing P/E of 34x, this single-digit growth profile may not justify its valuation premium.
- Valuation Remains Elevated: Despite the price crash, the trailing P/E of 34.24x is high for a company with single-digit revenue growth and high leverage. The forward P/E of 19.76x relies entirely on analyst forecasts for a significant earnings rebound that has yet to materialize.
VRSK Technical Analysis
The prevailing price trend is a pronounced and sustained downtrend, with the stock down 45.57% over the past year. The current price of $171.11 sits at just 9.1% of its 52-week range (52-week high: $322.92, 52-week low: $155.94), positioning it perilously close to its annual low, which suggests the stock is in a state of extreme technical weakness and could be considered a 'falling knife' by momentum investors. Recent momentum shows continued pressure, with the stock down 4.35% over the past month and 6.24% over the past three months, indicating the downtrend remains intact without signs of a meaningful reversal. This persistent negative momentum is starkly contrasted by the broader market's strength, as evidenced by the stock's severe negative relative strength of -73.45% over one year and -14.39% over three months. Key technical levels are clearly defined, with immediate support at the 52-week low of $155.94 and formidable resistance far above at the 52-week high of $322.92. A breakdown below the $155.94 support would signal a continuation of the bearish trend, while any recovery would need to overcome a massive overhead supply zone. The stock's beta of 0.726 indicates it has been less volatile than the market during this decline, which is unusual for a stock in a steep downtrend and may suggest the selling has been persistent but orderly.
Beta
0.73
0.73x market volatility
Max Drawdown
-51.2%
Largest decline past year
52-Week Range
$156-$323
Price range past year
Annual Return
-45.3%
Cumulative gain past year
| Period | VRSK Return | S&P 500 |
|---|---|---|
| 1m | -3.4% | +5.1% |
| 3m | -12.4% | +8.3% |
| 6m | -23.4% | +10.4% |
| 1y | -45.3% | +29.6% |
| ytd | -22.4% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRSK Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $778.8 million representing a 5.87% year-over-year increase. However, examining the sequential quarterly trend from the income statement reveals revenue has been relatively flat through 2025 ($753.0M in Q1, $772.6M in Q2, $768.3M in Q3, $778.8M in Q4), suggesting growth is stable but not accelerating. The company's single Insurance segment, which contributed $112.2 million in a disclosed period, is the sole driver of this top-line performance. Profitability remains robust with a net income of $197.2 million in Q4 2025, translating to a healthy net margin of 25.32%. Gross margin for the quarter was a strong 59.6%, though it has shown some variability compared to higher levels in prior 2025 quarters (e.g., 70.20% in Q2). The company is solidly profitable, and its trailing twelve-month free cash flow of $1.19 billion underscores strong cash generation. The balance sheet shows significant financial leverage with a debt-to-equity ratio of 16.30, which is exceptionally high and a key risk factor. Despite this leverage, liquidity appears adequate with a current ratio of 1.20, and the substantial free cash flow provides capacity to service debt. The return on equity of 293.95% is astronomically high, but this is largely a mathematical artifact of a very low equity base due to the high debt load, rather than an indicator of exceptional operational performance.
Quarterly Revenue
$778800000.0B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRSK Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 34.24x, while the forward PE is significantly lower at 19.76x, indicating the market expects a substantial recovery in earnings over the next year. This large gap suggests current depressed earnings are considered temporary, and analysts are forecasting improved profitability. Compared to industry averages, specific sector comparison data is not available in the provided dataset, preventing a quantified premium/discount analysis. However, a trailing PE of 34.24x for a company with single-digit revenue growth and high financial leverage would typically be considered rich unless exceptional future growth is anticipated. Historically, the stock's own valuation has compressed dramatically from extreme levels; for instance, its PE ratio was 39.43x at the end of Q4 2025 and has been as high as 426.45x in Q1 2023. The current 34.24x multiple is below its recent quarter-end reading but remains elevated relative to its own history when excluding the anomalous 2023 spike, suggesting the market may still be pricing in a recovery that has yet to materialize.
PE
34.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~130x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are dominated by extreme balance sheet leverage. The debt-to-equity ratio of 16.30 is exceptionally high and poses a significant refinancing and interest expense risk, particularly in a higher-for-longer rate environment. While strong free cash flow of $1.19 billion provides a serviceability cushion, any erosion in profitability—evidenced by the Q4 2025 gross margin decline to 59.6% from over 70% in prior quarters—could quickly pressure credit metrics. Furthermore, 100% revenue concentration in the Insurance segment creates vulnerability to a downturn in property-casualty underwriting cycles or client budget cuts.
Market & Competitive Risks include severe valuation compression, as the stock has already experienced a max drawdown of -51.19%. Despite this, a trailing P/E of 34.24x remains premium and is vulnerable to further de-rating if growth does not accelerate from its current ~6% pace. The stock's beta of 0.726 indicates it has been less volatile than the market during its decline, but its catastrophic -73.45% relative strength versus the S&P 500 highlights intense sector-specific or company-specific selling pressure that may not be over. Competitive disruption from insurtech or in-house analytics development by large insurers is a persistent threat to its moat.
Worst-Case Scenario involves a combination of rising interest rates increasing debt servicing costs, a recessionary hit to insurance industry IT budgets slowing revenue growth to zero, and a failed earnings rebound leading to multiple compression. This could trigger a breach of debt covenants, forcing asset sales or equity dilution at depressed prices. The realistic downside is a retest and break below the 52-week low of $155.94. From the current price of $171.11, this implies a potential further loss of approximately -9%. A more severe bear case, factoring in historical volatility, could see a drop toward the $140-$150 range, representing a downside of -12% to -18% from current levels.
FAQ
The key risks are, in order of severity: 1) Financial Risk: An exceptionally high debt-to-equity ratio of 16.30, which increases refinancing risk and interest expense sensitivity. 2) Technical & Sentiment Risk: The stock is in a severe downtrend, down 45.57% YoY and trading just above its 52-week low, indicating persistent selling pressure and poor momentum. 3) Growth Risk: Revenue growth is modest at 5.87% YoY and has been sequentially flat, which may not support a premium valuation. 4) Concentration Risk: 100% of revenue comes from the Insurance segment, making the company vulnerable to industry-specific downturns.
The 12-month forecast is bifurcated with a base case target range of $185-$220 (50% probability), a bull case of $240-$280 (25% probability), and a bear case of $140-$155 (25% probability). The most likely scenario is the base case, where the stock consolidates after its steep decline as stable fundamentals battle high leverage, leading to sideways action. The forecast hinges critically on whether the company's reported earnings begin to align with analyst expectations for a sharp recovery to an EPS of $12.35. Without that confirmation, the stock is likely to remain range-bound with a downward bias.
VRSK's valuation is conflicted. Based on trailing earnings and its modest ~6% revenue growth, its trailing P/E of 34.24x appears overvalued. However, the forward P/E of 19.76x, based on analyst expectations for a significant earnings rebound, suggests the market sees it as fairly valued or slightly undervalued if that recovery materializes. The key is that the valuation is not screamingly cheap because the high financial leverage justifies a risk discount. The stock is fairly valued for the substantial risks it carries, but not clearly undervalued enough to outweigh the powerful bearish technical momentum.
VRSK is a high-risk, potentially high-reward stock that is not a good buy for most investors at this time. For speculative, deep-value investors, the current price near multi-year lows and strong free cash flow of $1.19B may be appealing. However, the extreme debt-to-equity ratio of 16.3 and the severe, ongoing downtrend (down 45.57% in a year) present substantial risks. It could become a good buy if the stock establishes a sustained base above $180 and shows concrete progress in reducing leverage, but currently, it is more appropriate for a watchlist than a portfolio for the average investor.
VRSK is unsuitable for short-term trading due to its high volatility, negative momentum, and lack of near-term positive catalysts. It is only suitable for a long-term investment horizon of 3-5 years for investors who believe in the deep-value thesis. This extended timeframe is necessary to allow for a potential operational turnaround, debt reduction, and for the market to re-rate the stock once the technical damage is repaired. The stock's low beta of 0.726 is misleading given its specific bear market, and its lack of a meaningful dividend (yield 0.81%) provides no income support while waiting.